Seeking Alpha
 

Merck & Co Inc. (MRK)

- NYSE
  • Fri, May 29, 12:19 PM
    • Bayer's (OTCPK:BAYRY) (OTCPK:BAYZF) current #5 rank in the global animal health market could change once it divests its low margin plastics business either via an IPO or direct sale, possibly to a private equity firm. Analysts believe the unit could fetch as much as 11B euros ($12.1B).
    • CEO Marijn Dekkers says animal health is a "very attractive business for us. We've always looked with interest in it. It hasn't happened with us yet."
    • The top acquisition target would be Zoetis (ZTS +0.8%) which generated $4.8B in sales in 2014. Bayer will probably have competition, though. Valeant Pharmaceuticals (VRX -1.7%) and Merck (MRK +0.2%) have been mentioned as likely suitors.
    | 6 Comments
  • Wed, Jan. 21, 8:53 AM
    • Merck (NYSE:MRK) completes its acquisition of Cubist Pharmaceuticals (NASDAQ:CBST) for $102 per share. Over 58M CBST shares were tendered as of yesterday's expiration date representing 75.7% of Cubist's common stock.
    | Comment!
  • Dec. 18, 2014, 8:23 AM
    • Merck (NYSE:MRK) acquires privately-held Lausanne, Switzerland-based Oncoethix for an upfront payment of $110M and up to an additional $265M in clinical and regulatory milestones.
    • Oncoethix's lead product is OTX015, a BET bromodomain inhibitor (2,3,4) currently in Phase 1b development for the treatment of hematological malignancies and advanced solid tumors.
    • Bromodomain proteins 2,3 and 4 are considered potential cancer targets because of their pivotal role in regulating the transcription of growth-promoting genes and cell cycle regulators. In experimental models, the inhibition of BRD2/3/4 produced a potent antiproliferative effect associated with cell cycle arrest and cellular senescence.
    | Comment!
  • Dec. 16, 2014, 1:55 AM
    • Merck (NYSE:MRK) is approaching banks about an $8B, 364-day bridge loan to fund its acquisition of Cubist Pharmaceuticals (NASDAQ:CBST).
    • JP Morgan and Deutsche Bank are leading the deal.
    • Merck announced that it would buy Cubist on Dec. 8 for $9.5B.
    | 3 Comments
  • Dec. 8, 2014, 7:20 AM
    | 4 Comments
  • Dec. 7, 2014, 5:27 AM
    • Merck (NYSE:MRK) is in talks to buy Cubist Pharmaceuticals (NASDAQ:CBST), in a deal valued at more than $7B, Bloomberg reports.
    • Merck would pay about $100 per share. An offer in that range would represent a 34% premium over Cubist’s closing price on Dec. 5.
    • An agreement could be announced as early as this week.
    | 14 Comments
  • Nov. 24, 2014, 8:40 AM
    • Tetraphase Pharmaceuticals (NASDAQ:TTPH) is reportedly considering selling itself after being approached by interested suitors. Sources say the acquirer could be Acetelion (OTCPK:ALIOF) (OTC:ALIOY) or Roche (OTCQX:RHHBY).
    • The attraction is Tetraphase's antibiotic eravacycline, currently in Phase 3 development. Both oral and IV formulations of the drug have demonstrated higher dose response rates than Johnson & Johnson's (NYSE:JNJ) Levaquin (levofloxacin) for the treatment of complicated urinary tract infections. In the Ignite-2 study, patients receiving 200 mg eravacycline IV-to-oral doses achieved a response rate of 70.8% while patients receiving 250 mg IV-to-oral doses achieved 64.3%, both significantly ahead of Levaquin's 52.2% response rate.
    • A trial comparing eravacycline to Merck's (NYSE:MRK) Invanz (ertapenem) for the treatment of complicated intra-abdominal infections is underway.
    • TTPH is up 18% premarket on light volume.
    • Previously: Tetraphase completes eravacycline Phase 3 enrollment
    | Comment!
  • Oct. 19, 2014, 9:49 AM
    • Shire (NASDAQ:SHPG) may look to acquire an American rival after AbbVie pulled its proposed $55B takeover.
    • Possible targets include rare diseases specialist NPS Pharma (NASDAQ:NPSP) and Cubist Pharma (NASDAQ:CBST), which makes a treatment for superbug MRSA.
    • Source: Sunday Times
    | 2 Comments
  • Aug. 5, 2014, 7:46 AM
    • Merck (NYSE:MRK) finalizes its acquisition of Idenix Pharmaceuticals (NASDAQ:IDIX) for $24.50 per share. As of yesterday, 131,693,787 IDIX shares were tendered representing 82.5% of its outstanding common stock.
    | Comment!
  • Jul. 21, 2014, 8:56 AM
    • German private equity firm Aurelius has agreed to buy Reckitt Benckiser's (OTCPK:RBGLY) Scholl shoe business. The company is expecting the brand to expand internationally and maintain growth.
    • Aurelius will acquire the international rights to the business, except for North and South America, which will go to Bayer (OTCPK:BAYRY) as part of its $14B purchase of Merck (NYSE:MRK).
    • The deal is expected to close in the third quarter of 2014.
    | 1 Comment
  • Jun. 20, 2014, 8:13 AM
    • Merck (MRK) begins the process of acquiring Idenix Pharmaceuticals (IDIX) for $24.50 in cash. It will file a Schedule TO with the SEC today. Idenix will file a Schedule 14D-9 that includes the recommendation of the IDIX BOD that shareholders accept MRK's offer.
    | 3 Comments
  • Jun. 16, 2014, 3:48 PM
    • Merck (MRK -0.3%) shareholder Ronald Burns files suit (Burns vs Idenix Pharmaceuticals) attempting to block its $3.9B acquisition of Idenix (IDIX +1.4%) stating that the price undervalues IDIX. He cites IDIX's intrinsic value and a flawed process that prevents competing bids.
    • The deal includes a no-solicitation clause, grants MRK the right to match any superior offer and stipulates a $115.6M termination fee. Mr. Burns alleges that these clauses virtually assure Merck gets the deal.
    | 2 Comments
  • Jun. 12, 2014, 3:57 PM
    • At an investors meeting in Los Angeles, Merck (MRK -0.9%) EVP and President, Merck Research Laboratories Roger Perlmutter, M.D., Ph.D., says the company will consider large acquisitions as way to expand its product portfolio rather than obtain drug-development technologies. He says Merck continues to have an appetite for deals following its recent buy of Idenix (IDIX +0.3%) for $3.85B.
    | 3 Comments
  • Jun. 9, 2014, 7:59 AM
    • In an all-cash deal, Merck (MRK) acquires Hep C drug maker Idenix Pharmaceuticals (IDIX) for $24.50/share ($3.85B). The company has an attractive portfolio of Hep C product candidates based on nucleotide/nucleoside chemistry and prodrug technologies.
    | 19 Comments
  • May 13, 2014, 8:00 AM
    • Merck (MRK) has agreed to sell some ophthalmology products to Santen Pharmaceutical (SNPHY) for $600M upfront plus milestone payments.
    • The deal covers Japan, as well as "key markets" in Europe and Asia Pacific, with the products generating $400M in annual sales in those regions.
    • The transaction follows Merck's sale of its U.S. ophthalmology business to Akorn Pharmaceuticals.
    • Merck will continue to sell ophthalmology products in various markets, including Latin America, Canada, Australia, and EMEA. (PR)
    | Comment!
  • May 6, 2014, 6:13 AM
    • A deal between the two had been tipped last last week.
    • Merck's (MRK) consumer care business includes well-known brands like Claritin, Afrin, and Coppertone. "The combination of Merck Consumer Care's complementary portfolio of products and geographic reach with Bayer's will create a global consumer care business better positioned to serve consumers around the world," says Bayer (BAYZF, BAYRY) Chairman Dr. Marijn Dekkers.
    • Merck CEO Kenneth Frazier: "By unlocking value in Merck Consumer Care, we’re able to further our goal of being the premier research-intensive biopharmaceutical company through targeted investments that strengthen our product portfolio and enhance our pipeline.”
    • Source: Press Release
    | 2 Comments
Visit Seeking Alpha's
MRK vs. ETF Alternatives
Company Description
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.